901 reports of this reaction
4.6% of all SALMETEROL XINAFOATE reports
#3 most reported adverse reaction
ASTHMA is the #3 most commonly reported adverse reaction for SALMETEROL XINAFOATE, manufactured by GlaxoSmithKline LLC. There are 901 FDA adverse event reports linking SALMETEROL XINAFOATE to ASTHMA. This represents approximately 4.6% of all 19,705 adverse event reports for this drug.
Patients taking SALMETEROL XINAFOATE who experience asthma should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ASTHMA is moderately reported among SALMETEROL XINAFOATE users, representing a notable but not dominant share of adverse events.
In addition to asthma, the following adverse reactions have been reported for SALMETEROL XINAFOATE:
The following drugs have also been linked to asthma in FDA adverse event reports:
ASTHMA has been reported as an adverse event in 901 FDA reports for SALMETEROL XINAFOATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
ASTHMA accounts for approximately 4.6% of all adverse event reports for SALMETEROL XINAFOATE, making it one of the most commonly reported side effect.
If you experience asthma while taking SALMETEROL XINAFOATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.